Prestige BioPharma inks two new deals for its biosimilar trastuzumab
Category: #health  By Mateen Dalal  Date: 2019-07-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Prestige BioPharma inks two new deals for its biosimilar trastuzumab
  • The company would be able to supply and commercialize its biosimilar across Russia under the latest of the two deals.
     
  • The second deal, meanwhile, gives Prestige access to certain parts of Europe.

Prestige BioPharma (Prestige), a renowned Singapore-based biopharmaceutical company, has reportedly announced that it has signed two new agreements that would allow it to supply and commercialize its biosimilar trastuzumab, HD201, across Russia and parts of Europe.

Reports cite, the company signed the latest of the two deals with Pharmapark LLC, a private Russian pharmaceutical firm that is marketing five biosimilars across Russia at present. Meanwhile, the company inked the second deal with Mundipharma, a UK-based pharmaceutical company.

According to reports, the Mundipharma agreement would give the trastuzumab biosimilar access across a number of European countries including Spain, France, Sweden, Norway, Finland, Denmark, Austria, Switzerland and Portugal following the drug’s approval by the European Commission.

The CEO of Prestige BioPharma, Lisa S. Park, PhD, stated that the company is thrilled to collaborate with Mundipharma to commercialize its leading biosimilar across select European markets. Park further added that the proposed partnership is a crucial milestone for Prestige as it will boost the global availability of trastuzumab and benefit more patients through its accessibility and quality.

The new deals reportedly come as the latest in a string of agreements concerning the biosimilar for the Singapore-based biopharma company; in the fourth quarter of 2018, Prestige inked a licensing agreement with Cipla Limited to supply and commercialize trastuzumab across emerging markets. Earlier, the company also announced a deal with Alvogen to distribute the biosimilar across Eastern and Central Europe.

Sources familiar with the matter claim that the proposed biosimilar is currently being reviewed by the European Medicines Agency. Moreover, the company also plans to submit an application for the biosimilar with the U.S. FDA by the end of 2019.

Source Credits:

https://www.centerforbiosimilars.com/news/prestige-biopharma-strikes-2-more-deals-for-biosimilar-trastuzumab-hd201

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Gennova begins enrollment for Phase 1/2 trials of mRNA COVID vaccine
Gennova begins enrollment for Phase 1/2 trials of mRNA COVID vaccine
By Mateen Dalal

India's first mRNA-based COVID-19 vaccine, HGCO19, formulated by Pune-based biotech firm, Gennova Biopharmaceuticals is about to enter its Phase 1/2 clinical trials with the enrollment of candidates, said the Department of Biotechnology (DBT). R...

Mashcor launches new independent search engine for the Afrotech sector
Mashcor launches new independent search engine for the Afrotech sector
By Mateen Dalal

Mashcor, a leading South African digital agency, has reportedly announced the launch of Africa’s first indigenous search engine. The new search engine has been specifically designed to connect the region’s rapidly expanding tech sector to...

Canada and Germany ink new energy partnership with emphasis on hydrogen
Canada and Germany ink new energy partnership with emphasis on hydrogen
By Mateen Dalal

The government of Canada has inked a new, comprehensive energy partnership deal with the government of Germany to set up a formal collaboration across a wide array of shared energy priorities, including hydrogen and LNG. According to reports, this c...